Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enlicitide may help address unmet needs in ASCVD, a key driver of the ongoing cardiovascular (CV) epidemic RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the … [Read more…]

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

– Up to 72% placebo-adjusted mean reduction in fasting triglyceride levels at six months, with reductions sustained through 12 months – – 86% of olezarsen-treated patients achieved triglyceride levels less than 500 mg/dL, below the risk threshold for acute pancreatitis – – First and only investigational treatment for sHTG to significantly reduce acute pancreatitis events … [Read more…]

OMRON Releases the “Medium-Term Roadmap SF 2nd Stage”

KYOTO, Japan–(BUSINESS WIRE)–OMRON (TOKYO: 6645) has announced its “Medium-Term Roadmap Shaping the Future 2nd Stage (“SF 2nd Stage”),” covering from FY2026 to FY2030, on November 7, 2025 (JST). This Roadmap presents the Group’s vision and growth strategies through 2030, which are disclosed on our corporate website. Overview of the “Medium-Term Roadmap SF 2nd Stage” Since … [Read more…]

Gizmo Medical Redefines OEM Partnerships with Fully Customized Surgical Systems

Newly Available Capacity Unlocks Large-Scale Production for Global OEMs ST. CHARLES, IL–(BUSINESS WIRE)–Gizmo Medical, a global leader in orthopedic and surgical instrumentation design and production management, is redefining OEM partnerships through complete, turnkey instrumentation systems — trays, instruments, and accessories — precisely engineered to each customer’s full Bill of Materials (BOM). With its advanced global … [Read more…]

Kardigan Presents Positive Phase 2 Data on Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis at American Heart Association Scientific Sessions 2025

Results presented in oral session demonstrated that treatment with ataciguat reduced aortic valve calcium and improved cardiac function and output compared to placebo SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.–(BUSINESS WIRE)–Kardigan, a heart health company modernizing cardiovascular drug development, announced positive Phase 2 data on ataciguat in patients with moderate calcific aortic valve stenosis, presented … [Read more…]

Validation of FDA-Regulated Systems Used in Drug Development & Submissions Training Webinar: Using Artificial Intelligence (AI), Machine Learning (ML) & Large Language Models (LLMs), such as ChatGPT – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Validation of FDA-Regulated Systems Used in Drug Development & Submissions Using Artificial Intelligence (AI), Machine Learning (ML) & Large Language Models (LLMs), such as ChatGPT (August 28, 2025)” training has been added to ResearchAndMarkets.com’s offering. Providing safe and effective drugs and other FDA-regulated products is in the best interests of all those involved … [Read more…]

CMS Partners with Humata Health on Initiative to Make Clinical Approvals Faster, Fairer and More Efficient

Physician-led company to use its AI-driven solution to bring speed, transparency and clinical expertise to reduce unnecessary care and increase patient safety WINTER PARK, Fla.–(BUSINESS WIRE)–Humata Health, the leader in AI-powered prior authorization technology, has been selected by the Centers for Medicare & Medicaid (CMS) as a key partner for its WISeR model, an initiative … [Read more…]

NHC Reports Third Quarter 2025 Earnings

MURFREESBORO, Tenn.–(BUSINESS WIRE)–National HealthCare Corporation (NYSE American: NHC), the nation’s oldest publicly traded senior health care company, announced today net operating revenues for the quarter ended September 30, 2025 totaled $382,661,000 compared to $340,198,000 for the quarter ended September 30, 2024, an increase of 12.5%. The increase in net operating revenues for the third quarter … [Read more…]

Evinova China and Harbour BioMed Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development

SHANGHAI–(BUSINESS WIRE)–Yesterday, during the 8th China International Import Expo (“CIIE”), Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, and Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, … [Read more…]

Québec Expands Access to Dexcom CGM under the Régie de l’assurance maladie du Québec (RAMQ)

New RAMQ coverage means eligible Québec residents with type 2 diabetes on intensive insulin therapy can now access Dexcom Continuous Glucose Monitoring (CGM) to simplify diabetes management. MONTREAL–(BUSINESS WIRE)–Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, applauds the Québec government for its recent decision to expand coverage of Dexcom Continuous Glucose Monitoring (CGM) … [Read more…]